TY - JOUR AU - Palloni, Andrea AU - Frega, Giorgio AU - De Lorenzo, Stefania AU - Rizzo, Alessandro AU - Abbati, Francesca AU - Deserti, Marzia AU - Tavolari, Simona AU - Brandi, Giovanni PY - 2018 TI - Adjuvant treatment in biliary tract cancer JF - Translational Cancer Research; Vol 8, Supplement 3 (April 17, 2019): Translational Cancer Research (Primary Liver Cancer) Y2 - 2018 KW - N2 - Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients’ long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with high-risk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care. UR - https://tcr.amegroups.org/article/view/23744